Zydus Cadila, the group company, has received final approval from the US Food and Drug Administration to market Methylprednisolone tablets USP in the strengths of 4 mg, 8 mg, 16 mg and 32 mg.
Cadila Healthcare share price gained nearly 3 percent intraday Thursday following approval from the US health regulator for Methylprednisolone tablets & Cinacalcet Hydrochloride tablets.
Zydus Cadila, the group company, has received final approval from the US Food and Drug Administration to market Methylprednisolone tablets USP in the strengths of 4 mg, 8 mg, 16 mg and 32 mg.
It is used to treat conditions such as arthritis, blood disorders, severe allergic reactions, certain cancers, eye conditions, skin/kidney/intestinal/lung diseases and immune system disorders.
It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
The group also received the final approval to market Cinacalcet Hydrochloride Tablets, which is indicated for the treatment of high blood calcium in patients with cancer of parathyroid glands and for the treatment of high blood parathyroid hormone levels seen in patients with chronic kidney diseases on dialysis.
Cinacalcet will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.
The Cadila Group now has more than 185 approvals.
At 12:25 hours IST, the stock price was quoting at Rs 406.65, up Rs 4.45, or 1.11 percent on the BSE.